1.Expression of Wnt5a gene in breast cancer cell line MCF-7 and its relationship with E-cadherin or vimentin
Xia QIU ; Guorong YANG ; Li LIU ; Yong HUANG ; Ruolan ZENG ; Xiaoyi YAO ; Jing SHI ; Zhifo WU ; Ling WANG ; Gui LIU ; Xinjia CAI ; Junhui HUANG
Cancer Research and Clinic 2016;28(10):649-653
Objective To investigate the relationship between Wnt5a gene and E-cadherin or vimentin gene in breast cancer cell line MCF-7. Methods RT-PCR was used to detect the mRNA expression of Wnt5a, E-cadherin and vimentin in breast cancer MCF-7 cells and the normal human mammary epithelial cell line MCF-10A, respectively, and their correlation was analyzed. Results The mRNA expression levels of Wnt5a and E-cadherin in cell line MCF-7 were significantly lower than those in cell line MCF-10A [(16.93± 2.97)%vs. (27.47±2.76) %, (12.97±1.35) % vs. (20.43±2.60) %, both P<0.05]. The mRNA expression level of vimentin in cell line MCF-7 was significantly higher than that in cell line MCF-10A [(16.53±0.85)%(6.33± 2.08) %, P<0.05 ]. In cell line MCF-7, the expression of Wnt5a was positively related to E-cadherin (г=0.997, P<0.05), but it was negatively related to vimentin (г=-0.998, P<0.05). Conclusions The expression of Wnt5a in human breast cancer cell line MCF-7 is significantly lower than that in cell line MCF-10A, which indicates that Wnt5a is a cancer suppressor gene in breast cancer. The expression of Wnt5a in cell line MCF-7 is positively related with E-cadherin, and it is negatively related with vimentin. Wnt5a may cause invasion and metastasis of breast cancer cell through the breast epithelial mesenchymal transitions.
2.Treatment progress of mantle cell lymphoma
Ruolan ZENG ; Yajun LI ; Hui ZHOU
Journal of Leukemia & Lymphoma 2018;27(1):12-15
Mantle cell lymphoma (MCL) is an unique B-cell non-Hodgkin lymphoma with aggressive biological behavior, high malignancy, fast progress, bad reaction to the normal treatment, short remission after the standard treatment, which is still considered as the an incurable lymphoma type. The 59th American Society of Hematology Annual Meeting covered progress of the new target exploration of MCL, the drug resistance study and the optimization of clinical trails. The paper discusses the progress of MCL treatment according to the meeting literatures.